Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer: Implications for management

Cancer

Volumn 113, Issue 11, 2008, Pages 3146-3152

  Nguyen, Paul L ^a   Chen, Ming Hui ^b   Catalona, William J ^c   Alexander, Brian M ^a   Roehl, Kimberly A ^d   Loeb, Stacy ^e   D'Amico, Anthony V ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Incident cancer; Initial screening; Prevalent cancer; Prostate cancer; Prostate specific antigen; Prostatectomy; Serial screening; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; DISEASE FREE SURVIVAL; HUMAN; MALE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; RECURRENT DISEASE; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TREATMENT OUTCOME;

EID: 56649110357     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23926     Document Type: Article

References (22)

1. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289:1414-1420. (Pubitemid 37430309)
2. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6 suppl):251S-272S.
3. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006;3:CD004720.
4. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999;38:83-91. (Pubitemid 29052946)
5. Schroder FH. The European Screening Study for Prostate Cancer. Can J Oncol. 1994;4(suppl 1):102-105; discussion 106-109.
6. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer. 2004;100:1397-1405. (Pubitemid 38366842)
7. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet. 1994;343:251-254. (Pubitemid 24039623)
8. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
9. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172(4 pt 1):1297-1301. (Pubitemid 39249701)
10. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954. (Pubitemid 23244733)
11. van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, Schroder FH. Tumor characteristics and prognostic factors in 2 subsequent screening rounds with 4-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology. 2006;68:615-620. (Pubitemid 44436477)
12. Cagiannos I, Karakiewicz P, Graefen M, et al. Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol. 2004;171(2 pt 1):692-696. (Pubitemid 38090458)
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166:416-419. (Pubitemid 32652213)
15. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376-3385.
16. Smith EB, Frierson HF Jr, Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer. 2002;94:2282-2287. (Pubitemid 34411988)
17. Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A. The Gleason score shift: score 4 and 7 years ago. Int J Radiat Oncol Biol Phys. 2003;56:1241-1247. (Pubitemid 36842874)
18. Harnden P, Shelley MD, Clements H, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer. 2007;109:13-24. (Pubitemid 46120190)
19. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol. 2007;8:411-419. (Pubitemid 46621769)
20. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
21. Patel DA, Presti JC Jr, McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005;23:6157-6162.
22. Walsh PC. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. J Urol. 2005;173:830.